Roxadustat treatment for erythropoiesis-stimulating agent-hyporesponsive anemia in maintenance hemodialysis patients

OBJECTIVE: Hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) is a prevalent problem affecting hemodialysis (HD) patients. Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and regulates iron metabolism. We explored the ability of...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Jie, Chen, Xiaojun, Zhou, Linshan, Yu, Weihong, Liu, Hong, Yuan, Fang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Observational Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583527/
https://www.ncbi.nlm.nih.gov/pubmed/37843847
http://dx.doi.org/10.1177/03000605231204475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583527/
https://www.ncbi.nlm.nih.gov/pubmed/37843847
http://dx.doi.org/10.1177/03000605231204475

Ejemplares similares